生物技术公司Ocular Therapeutix™近日公布了其核心产品Axpaxli™用于治疗湿性年龄相关性黄斑变性的里程碑式Sol-1三期临床试验的最新积极结果。此次发布的数据聚焦于第52周的疗效与安全性评估，进一步验证了该疗法的持久性与可靠性。
试验数据显示，在第52周的时间点，Axpaxli™继续展现出显著的临床获益。主要终点和关键次要终点均达到统计学意义，凸显了其在长期管理湿性年龄相关性黄斑变性方面的潜力。该结果不仅巩固了早期分析的结论，也为后续的监管申报提供了强有力的支持。
安全性方面，Axpaxli™在第52周的整体耐受性良好，其安全性与先前报告的数据一致，未发现新的安全性信号。这一积极进展标志着Ocular Therapeutix在眼科创新疗法开发领域迈出了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.